TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06548360: A Phase 3, Randomized, Double-Blind, Safety, and Efficacy Study of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo

Sponsor: Incyte Corporation · Phase: PHASE3 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 180 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$439,632

Rescue Site Savings

+$293,088

Unlock Full NCT06548360 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06548360 Rescue Dossier →